1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Much Ado About Nothing Much With Atara's MS Hopeful

Interim Analysis On ATA188 Reveals Little

 
• By Kevin Grogan

Investors and most analysts were not impressed with a much-anticipated Phase II update on Atara’s allogeneic T-cell immunotherapy which could be transformational as a treatment for multiple sclerosis, but some observers believe the slump in the firm’s stock was not merited.

2023
Atara builds towards a successful 2023 when its multiple sclerosis data will read out • Source: Shutterstock

Atara Biotherapeutics, Inc.'s eagerly awaited update on ATA188, its investigational off-the-shelf T-cell candidate for multiple sclerosis, turned out to be less than gripping, leaving analysts underwhelmed and investors spooked.

The company, which has developed a platform based on using Epstein Barr virus (EBV) T-cells from healthy donors to develop...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

In Brief: PolyPid’s D-PLEX100 Aces Phase III Trial, US Partner, Submission Eyed

 
• By Sushmita Panda

PolyPid's D-PLEX100 meets Phase III endpoints this time around, significantly reducing surgical point infections in abdominal colorectal surgery, and is set for a US approval submission early next year.

Insmed’s PAH Data Indicate Potential To Surpass Established Therapies

 
• By Joseph Haas

Insmed’s inhaled treprostinil exceeded goals for reducing pulmonary vascular resistance and improving six-minute walk test distance in Phase IIb data.

NewAmsterdam’s CETP Inhibitor Improves Alzheimer’s Biomarkers

 
• By Mandy Jackson

Data from the BROADWAY trial testing LDL-C reduction in adults with ASCVD showed that obicetrapib improved Alzheimer’s disease biomarkers, including tau and amyloid. Analysts think the data could differentiate obicetrapib against competitors in the cholesterol market.

Genmab Looks To Keep Ahead Of Lilly In Folate ADCs

 
• By Andrew McConaghie

The firm has its ‘foot on the gas’ to accelerate development of its FRα-targeting antibody-drug conjugate, Rina-S, but rival Lilly is also moving rapidly into Phase III.

More from R&D

Genmab Looks To Keep Ahead Of Lilly In Folate ADCs

 
• By Andrew McConaghie

The firm has its ‘foot on the gas’ to accelerate development of its FRα-targeting antibody-drug conjugate, Rina-S, but rival Lilly is also moving rapidly into Phase III.

Metsera’s Amylin Analog Stars In Obesity Phase I

 
• By Joseph Haas

Intended as obesity monotherapy and for combination with the firm’s GLP-1 analog, MET-0233i showed best-in-class efficacy with placebo-like tolerability at low doses.

Merck & Co.’s Enlicitide Poised To Be First Oral PCSK9 Inhibitor To Market

 
• By Jessica Merrill

The company announced positive data from two Phase III trials testing the cholesterol-lowering medicine.